Short Interest in Bio-Path Holdings, Inc. (NASDAQ:BPTH) Grows By 179.6%

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 86,400 shares, a growth of 179.6% from the November 30th total of 30,900 shares. Based on an average daily trading volume, of 3,000,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 2.0% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Bio-Path in a report on Thursday. They set a “sell” rating on the stock.

Bio-Path Stock Performance

BPTH stock traded down $0.21 during trading on Friday, hitting $1.14. The company had a trading volume of 491,588 shares, compared to its average volume of 1,509,598. The firm has a 50-day moving average price of $0.89 and a 200-day moving average price of $1.24. Bio-Path has a 12 month low of $0.59 and a 12 month high of $12.00.

Hedge Funds Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent quarter. Institutional investors own 5.74% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.